How should I taper budesonide in a patient with suspected Crohn’s disease, elevated fecal calprotectin, duodenitis and gastritis on EGD, who is now on one tablet daily, wishes to stop the medication, and has a recent diagnosis of mast cell activation syndrome (MCAS)?

Discontinuation of Budesonide in This Clinical Context

You should not abruptly stop budesonide but instead pursue a gradual taper over 1-2 weeks, while recognizing that the diagnosis remains uncertain and the patient may not have Crohn's disease at all. The clinical picture—duodenitis and gastritis on EGD without typical Crohn's findings, plus recent MCAS diagnosis—suggests alternative explanations for symptoms that responded to budesonide.

Critical Diagnostic Considerations

Your patient lacks a confirmed Crohn's disease diagnosis. The evidence shows:

• EGD findings of duodenitis/gastritis are not diagnostic of Crohn's disease
• Elevated fecal calprotectin is non-specific and can be elevated in MCAS, gastritis, NSAID use, and other conditions 1, 2
• No ileocolonoscopy or small bowel imaging documented to confirm typical Crohn's pathology
• The recent MCAS diagnosis may explain both GI symptoms and elevated inflammatory markers

The response to budesonide does not confirm Crohn's disease. Budesonide has documented efficacy in mastocytic enterocolitis refractory to standard mast cell stabilizers 3, and corticosteroids are part of the treatment algorithm for MCAS symptom management 4.

Budesonide Tapering Protocol

Based on guideline evidence for Crohn's disease (the closest applicable condition), when remission is achieved with budesonide, it should be tapered over 1-2 weeks 5. The specific taper from one tablet daily (assuming 3mg capsules = 3mg daily, or 9mg extended-release = 9mg daily):

If on 9mg daily:

• Taper to 6mg daily for 1 week
• Then 3mg daily for 1 week
• Then discontinue

If on 3mg daily:

• May discontinue after 1 week at current dose or taper more gradually if concerned about adrenal suppression

Important caveat: The FDA label warns that prolonged budesonide use can cause adrenal suppression 6. While budesonide has lower systemic effects than prednisone, patients on chronic therapy may need HPA axis monitoring, particularly if they've been on treatment for several months.

Why Budesonide Should NOT Be Used for Maintenance

Multiple high-quality guidelines strongly recommend against using budesonide for maintenance therapy in Crohn's disease 7. The Canadian Association of Gastroenterology states: "In patients with mild to moderate Crohn's disease, we suggest against the use of oral budesonide to maintain complete remission" (conditional recommendation, low-quality evidence) 7.

The British Society of Gastroenterology 2019 guidelines note that corticosteroids including budesonide "are not effective" for maintenance 8, and the 2025 update reaffirms that "corticosteroids are not recommended for maintenance of remission in patients with Crohn's disease" 9.

Alternative Diagnostic and Management Approach

Given the clinical uncertainty, consider:

1. Pursue definitive Crohn's diagnosis before assuming this is the correct diagnosis:

   • Ileocolonoscopy with biopsies (if not already done)
   • MR enterography or CT enterography to assess small bowel
   • Repeat fecal calprotectin after stopping budesonide to see if it remains elevated

2. Address the MCAS diagnosis appropriately:

   • Optimize MCAS therapy with H1/H2 antihistamines, mast cell stabilizers (cromolyn sodium), and leukotriene inhibitors as first-line 4
   • Consider whether gastritis/duodenitis represents mast cell infiltration rather than Crohn's disease

3. Treat the documented gastritis/duodenitis:

   • Proton pump inhibitors are appropriate for gastroduodenal inflammation 8
   • This may explain symptom improvement independent of any IBD effect

Monitoring After Discontinuation

Check fecal calprotectin 4-8 weeks after stopping budesonide to establish a new baseline 1, 2. If calprotectin normalizes (<50 μg/g), this further questions the Crohn's diagnosis. If it remains elevated (>150 μg/g) with symptom recurrence, pursue complete diagnostic workup before restarting therapy.

The evidence shows that fecal calprotectin >115 μg/g predicts disease progression in confirmed Crohn's disease 10, but this threshold is only meaningful once the diagnosis is established.

Key Pitfalls to Avoid

• Do not assume Crohn's disease without typical findings on ileocolonoscopy or cross-sectional imaging
• Do not continue budesonide long-term for maintenance—this is ineffective and risks adrenal suppression 8, 7, 9
• Do not ignore the MCAS diagnosis—this may be the primary driver of symptoms and inflammation
• Do not abruptly stop budesonide—taper over 1-2 weeks to avoid potential adrenal insufficiency, especially if used for >8 weeks 6